Vivos Therapeutics Files 8-K on Shareholder Vote Matters

TL;DR

Vivos Therapeutics held a shareholder vote on Nov 26th, details filed today.

AI Summary

Vivos Therapeutics, Inc. filed an 8-K on November 27, 2024, reporting on matters submitted to a vote of security holders on November 26, 2024. The filing details the company's corporate structure, including its state of incorporation (Delaware) and principal executive offices in Littleton, Colorado.

Why It Matters

This filing indicates that Vivos Therapeutics held a shareholder vote, which could pertain to significant corporate decisions or changes that may impact the company's future direction and shareholder value.

Risk Assessment

Risk Level: low — The filing is a routine disclosure of a shareholder vote and does not contain information about significant financial distress or major operational changes.

Key Players & Entities

• Vivos Therapeutics, Inc. (company) — Registrant
• November 27, 2024 (date) — Date of Report
• November 26, 2024 (date) — Date of earliest event reported
• Delaware (jurisdiction) — State of incorporation
• Littleton, Colorado (location) — Principal executive offices

FAQ

Key Financial Figures

• $0.0001 — ch registered Common Stock, par value $0.0001 per share VVOS The NASDAQ Stock Mar

Filing Documents

• form8-k.htm (8-K) — 56KB
• 0001493152-24-048065.txt ( ) — 230KB
• vvos-20241127.xsd (EX-101.SCH) — 3KB
• vvos-20241127_lab.xml (EX-101.LAB) — 33KB
• vvos-20241127_pre.xml (EX-101.PRE) — 24KB
• form8-k_htm.xml (XML) — 4KB

From the Filing

UNITED SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 27, 2024 (November 26, 2024) Vivos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39796 81-3224056 (State or other jurisdiction (Commission (I.R.S. Employer of incorporation) File Number) Identification No.) 7921 Southpark Plaza , Suite 210 Littleton , Colorado 80120 (Address of principal executive offices) (Zip Code) (866) 908-4867 (Registrant's telephone number, including area code) N/A (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.0001 per share VVOS The NASDAQ Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (240.12b-2 of this chapter). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Item 5.07 Submission of Matters to a Vote of Security Holders. On November 26, 2024, Vivos Therapeutics, Inc. (the "Company") conducted its 2024 annual meeting of stockholders (the "Annual Meeting"). The number of shares of common stock of the Company entitled to vote at the Annual Meeting was 4,765,300 shares outstanding as of the October 4, 2024 record date (the "Voting Stock"). No other shares of the Company's capital stock were entitled to vote at the Annual Meeting. The number of shares of Voting Stock present or represented by valid proxy at the Annual Meeting was approximately 2,695,565 shares of Voting Stock, constituting a quorum. At the Annual Meeting, the Company's stockholders: (i) elected each of R. Kirk Huntsman, Dr. Ralph Green, Anja Krammer, Mark Lindsay, Leonard Sokolow and Dr. Matthew Thompson (collectively, the "Director Nominees") to serve as directors on the Company's Board of Directors (the "Board") for a one-year term that expires at the 2025 Annual Meeting of Stockholders, or until their earlier death, resignation or removal and their successors are elected and qualified; (ii) approved and adopted the Company's proposed 2024 Omnibus Equity Incentive Plan (the "2024 Plan") and the issuance of contingent awards under the 2024 Plan to certain Company officers, employees and consultants; and (iii) ratified the appointment of Moss Adams LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024. The following is a tabulation of the voting on the proposals presented at the Annual Meeting: Proposal No. 1 – Election of Directors R. Kirk Huntsman, Dr. Ralph Green, Anja Krammer, Mark Lindsay, Leonard Sokolow and Dr. Matthew Thompson were each elected as a director to serve for a one-year term that expires at the 2025 annual meeting of stockholders or until a successor is elected and qualified or until her or his earlier death, incapacity, removal or resignation. The voting results were as follows: Nominee Shares Voted For Shares Withheld Broker Non-Vote R. Kirk Huntsman 1,123,786 155,299 1,415,480 Dr. Ralph Green 1,086,059 193,026 1,415,480 Anja Krammer 1,092,052 187,033 1,415,480 Mark Lindsay 1,124,404 155,081 1,415,480 Leonard Sokolow 1,092,216 186,689 1,415,480 Dr. Matthew Thompson 1,104,743 174,342 1,415,480 Proposal No. 2 – Approval of Company's Proposed 2024 Omnibus Equity Incentive Plan and Contingent Awards Approved and adopted the Company's proposed 2024 Omnibus Equity Incentive Plan (the "2024 Plan") and the issuance of contingent awards under the 2024 Plan to certain Company officers, employees and consultants. The voting results were as follows: Shares Voted For Shares Voted Against Shares Abstaining Broker Non-Vote 957,268 313,560 17,747 1,415,480 Proposal No. 3 – Ratification of the appo

View Full Filing

View this 8-K filing on SEC EDGAR